An Early Stage  ASX Company with Great Upside Potential

Vitrafy reported strong FY26 results highlighting a smooth transition towards commercialisation. Key milestone across blood preservation and U.S. market expansion further strengthened its growth outlook.

Vitrafy Life Sciences Limited (ASX: VFY)

Vitrafy Life Sciences Limited (ASX: VFY), as on 4 August 2026, published its full year reports indicating a major turnaround year for the company as it decisively moved from development to commercialisation stage by transforming years of research into independent validation of cryopreservation ecosystem from U.S. military and conversion of that validation into growing commercial opportunities in U.S. blood market.

The company has a market capitalisation of $281.32 million and has made significant progress across its commercialisation strategy during FY26. Its Phase II platelet study with the U.S. Army Institute of Surgical Research (USAISR) achieved 94.4% mean post-thaw platelet recovery, exceeding the 75% U.S. fresh guideline and 50% European standard. This validation supported agreements with Vitalant and Hoxworth Blood Center, expanding Vitrafy’s reach into the civilian U.S. blood market.

The company also transitioned Guardion from design into Research Use Only manufacturing, launched its LifeChain cloud platform, built its first 10 Guardion units, established U.S. operations and added seven employees to support its growing commercial activities.

Commercial Opportunities Expand Beyond Blood

Vitrafy also advanced opportunities across animal reproduction and cell and gene therapy (CGT). The company secured a global partnership with IMV Technologies to co-develop a global go-to-market offering, while continuing its aquaculture programs with existing partners. These activities helped animal-health revenue increase 159% from previous year to $169,000.

In CGT, Vitrafy launched its technology into the U.S. market and began engaging therapy developers and contract development and manufacturing organisations (CDMOs). With around 1,800 manufacturers and 300 CDMOs operating across the North American CGT market, Vitrafy is progressing discussions towards its first revenue-generating CGT agreement.

Financial Performance

The company was in its investment phase as it built the infrastructure required for commercial scale. Revenue and other income increased 80% to $3.66 million, while its net loss narrowed 50.6% to $16.17 million, compared with $32.71 million in FY25. The company ended the year with $41.2 million in cash and term deposits which was supported by a $30 million institutional placement, while a further $2 million was raised through its Share Purchase Plan after year-end. The strengthened balance sheet provides funding to expand U.S. operations, increase Guardion manufacturing and support the next stage of commercialisation.

Rising Demand Meets a Shrinking Blood Supply

The U.S. blood market is facing growing pressure as demand rises while available supply declines. Since 2013, the U.S. population aged 65+ has increased by 30%, which significantly outpaced the 6% growth in the overall population, increasing the need for blood products from an ageing population. At the same time, red blood cell collections have fallen 19%, tightening available supply. The situation has become increasingly critical, with the American Red Cross declaring a national blood “crisis” in July 2026. Vitrafy is addressing this imbalance through cryopreservation, which could shift blood from a highly perishable product towards a more stable inventory model by enabling longer-term stockpiling and reducing wastage, including the estimated US$280 million of platelets discarded annually due to expiry.

Outlook

FY27 is set to focus on converting Vitrafy’s scientific validation and growing commercial pipeline into deployments and revenue.

The company plans to manufacture another 15 Guardion units during the first half, establish U.S. manufacturing capability and progress Guardion towards FDA medical-device registration in 1H FY27. Vitrafy is also targeting its first revenue-generating CGT agreement during the first half, alongside further development of its Vitalant, Hoxworth and IMV relationships. With its U.S. platform now established and a strong funding position, the company enters FY27 focused on scaling manufacturing, converting partnerships into commercial opportunities and expanding adoption of its cryopreservation ecosystem.

(Source: Company Announcements)